Vertex to acquire rights to cystic fibrosis treatment for $1.6m

09-03-2017

Vertex to acquire rights to cystic fibrosis treatment for $1.6m

Choreograph / iStockphoto.com

US-based Vertex Pharmaceuticals has agreed to acquire a potential treatment for cystic fibrosis from Concert Pharmaceuticals, also in the US, for $160 million.


Vertex Pharmaceuticals, Concert Pharmaceuticals, acquisition, M&A, cystic fibrosis, development, commercial rights

LSIPR